Respiratory
2 drugs are in development for Idiopathic Pulmonary Fibrosis.
- Companies
- 2
- Clinical trials
- 29
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Idiopathic Pulmonary Fibrosis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| mn-001 | MEDICINOVA INC (MNOV) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| tti-101 | Tvardi Therapeutics, Inc. (TVRD) |
About this indication
Idiopathic Pulmonary Fibrosis context
Respiratory·MeSH: Idiopathic Pulmonary Fibrosis (D054990)
Also known as: Cryptogenic Fibrosing Alveolitides, Cryptogenic Fibrosing Alveolitis, Dysplasia, Fibrocystic Pulmonary, Fibrocystic Pulmonary Dysplasias, Idiopathic Fibrosing Alveolitis, Chronic Form, Idiopathic Pulmonary Fibroses
Incidence
6.8 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Idiopathic Pulmonary Fibrosis?
BioSniper tracks 2 drugs in development for Idiopathic Pulmonary Fibrosis across 2 companies.
How many clinical trials target Idiopathic Pulmonary Fibrosis?
There are 29 clinical trials targeting Idiopathic Pulmonary Fibrosis tracked by BioSniper.